BioVie Inc. (NASDAQ:BIVIW – Get Free Report) shares passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $0.32 and traded as low as $0.2908. BioVie shares last traded at $0.2908, with a volume of 903 shares traded.
BioVie Trading Up 6.2%
The firm’s fifty day simple moving average is $0.31 and its 200 day simple moving average is $0.32.
BioVie Inc is a clinical-stage biopharmaceutical company developing treatments for liver and neurological disorders. Its research includes therapies for conditions associated with inflammation and impaired organ function.
The company’s development programs include BIV201, an investigational continuous-infusion formulation of terlipressin being studied for ascites associated with cirrhosis, and NE3107, an investigational oral drug candidate being studied for neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease.
Recommended Stories
- Five stocks we like better than BioVie
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.
